The FDA added an eye warning to GLP-1 medications. Should you be worried?

By Ayushi Dixit, MD, Endocrinologist · November 2026

If you take Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, you may have seen headlines this week about vision loss. On November 9, 2026, the U.S. Food and Drug Administration announced that it is requiring the makers of all GLP-1 receptor agonist medications to add a warning about a rare eye condition called NAION to their labels (FDA Drug Safety Communication).

Several patients have already asked me whether they should stop their medication. The short answer: please don't stop on your own. Here is what the FDA found, what the warning means in real numbers, and the symptoms worth knowing.

What is NAION?

NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front of the optic nerve drops, and it is sometimes described as an "eye stroke." The FDA describes it as a rare condition that can cause sudden, painless loss of vision in one eye, which can be permanent (FDA).

The exact cause isn't fully understood. According to the FDA, risk factors may include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease. Many of these are the same conditions that GLP-1 medications are prescribed to help, which is one reason this question has been hard to study.

What the FDA actually found

The question first drew wide attention in 2024, when a study from Massachusetts researchers reported a possible link between semaglutide and NAION (Hathaway et al., JAMA Ophthalmology, 2024). The FDA then reviewed clinical trial data, real-world data, animal studies, and case reports.

Its key findings, in plain terms:

  • The risk is rare. Across 126 clinical trials, NAION occurred at a rate of 6.4 cases per 100,000 person-years in people taking a GLP-1, compared with 3.8 per 100,000 person-years in people taking a placebo or a different diabetes medicine. A "person-year" is one person followed for one year.
  • The real-world picture is mixed. In an FDA study of adults with type 2 diabetes, the rate of NAION with GLP-1s was not significantly different from the rate with SGLT-2 inhibitors (another common diabetes medicine class), but it was higher than with DPP-4 inhibitors.
  • The warning covers the whole class. It applies to every FDA-approved GLP-1, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide, dulaglutide, and the newer oral pill orforglipron (Foundayo).

Eye specialists have urged calm. The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society said NAION is rare, any added risk appears small, and it has not been established that these medications cause NAION (AAO via Newswise). Their message to patients was simple: don't stop your medication without talking to your doctor, and see an ophthalmologist promptly if you notice sudden, painless vision loss in one eye.

Symptoms to know

The FDA lists these warning signs of NAION:

  • Sudden, painless vision loss in one eye, often noticed on waking
  • Blurred or missing areas of vision, such as blind spots or tunnel vision
  • Colors that look faded or distorted
  • Blurry or hazy spots in the center of your vision

If you notice any of these, contact your doctor right away and get a prompt eye exam. Sudden vision loss always needs same-day attention, whatever the cause. If you can't reach your doctor, go to an emergency room.

Should you stop your GLP-1?

For most people, no. Not without a conversation first. GLP-1 medications are FDA-approved for type 2 diabetes and for chronic weight management, and certain ones are also approved to lower the risk of heart attack and stroke in some adults with heart disease, to protect the kidneys in some people with diabetes and kidney disease, and to treat moderate to severe sleep apnea in adults with obesity (FDA). Stopping suddenly can mean losing those benefits.

Here's how I'd think about it:

  1. No eye symptoms? Keep taking your medication as prescribed, and bring your questions to your next visit. The ophthalmology groups say routine eye exams just to check NAION risk before starting a GLP-1 aren't recommended based on current evidence.
  2. Have diabetes? Keep your regularly scheduled diabetic eye exams. That advice hasn't changed.
  3. Ever had NAION, or a "stroke" in the eye? Tell your prescriber before starting or continuing a GLP-1. The FDA notes that NAION can recur, and having it in one eye raises the risk in the other.
  4. Diagnosed with NAION while on a GLP-1? The FDA advises prescribers to consider stopping the medication unless the benefits clearly outweigh the risk. That decision is best made together by you, your eye doctor, and the doctor who prescribes your GLP-1 (Ophthalmology Times).

Why it matters who prescribes your GLP-1

A label update like this is a good reminder that GLP-1s are serious medications, not a quick online checkout. (I wrote more about this in Getting a GLP-1 Online? What to Know Before You Start.) Before starting a GLP-1, I review your full medical history, including your eyes, blood pressure, sleep, kidney function, and any history of pancreatitis, gallbladder disease, or thyroid cancer in the family. We also talk about how you'll protect muscle and bone as you lose weight, and what the plan is if side effects come up.

In my practice, I prescribe only FDA-approved GLP-1 medications. I don't prescribe compounded versions. And I check in regularly, so a new symptom like a change in vision gets addressed quickly instead of waiting months.

GLP-1 and weight management care on the Upper East Side

I'm a triple board-certified physician in Endocrinology, Internal Medicine, and Obesity Medicine. I see patients in person Wednesday through Friday at my office at 19 East 80th Street on the Upper East Side, by telehealth anywhere in New York and New Jersey, and through private home visits.

Whether you're thinking about starting a GLP-1, already on one and have questions about this warning, or managing diabetes alongside your weight, a visit for medical weight management and GLP-1 care includes a full review of your health history, current medications, and goals. You leave with a written plan, and results vary from person to person.

Not sure where to start? New patients can book a free 15-minute discovery call to learn how the practice works and whether it's a good fit. (The call is an introduction, not a medical visit, so no medical advice is given.) Ready for a full consultation? Book a visit or see our fees and FAQ.


Medical disclaimer: This article is for general education only. It is not medical advice and does not create a doctor-patient relationship. GLP-1 medications aren't right for everyone, and benefits, risks, and results vary from person to person. Talk with your own healthcare provider before starting, stopping, or changing any medication. If you have sudden vision loss or another medical emergency, call 911 or go to the nearest emergency room. This article is not sponsored and does not endorse any specific product.

Sources

  1. U.S. Food and Drug Administration. "FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition." Drug Safety Communication, November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  2. American Academy of Ophthalmology. "Here's What You Need To Know About the FDA's New GLP-1 Warning." Newswise, November 2026. https://www.newswise.com/articles/here-s-what-you-need-to-know-about-the-fda-s-new-glp-1-warning
  3. American Academy of Ophthalmology. "Can Ozempic Affect Eye Health? Here's What Ophthalmologists Want You to Know." https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-here-s-what-ophthalm
  4. Ophthalmology Times. "FDA requires NAION warning across the GLP-1 receptor agonist class." November 2026. https://www.ophthalmologytimes.com/view/fda-requires-naion-warning-across-the-glp-1-receptor-agonist-class
  5. Hathaway JT, et al. "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide." JAMA Ophthalmology. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296
Next
Next

Getting a GLP-1 Online? What to Know Before You Start